Arizona Alzheimer's Disease Research Center

亚利桑那州阿尔茨海默病研究中心

• 批准号: 10264187
• 负责人: ERIC MICHAEL REIMAN
• 金额: $ 321.7万
• 依托单位: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-05 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10264187
• 关键词: Address; Adult; Affect; Aging; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Area; Arizona; Autopsy; Biological; Biological Markers; Blood Tests; Blood specimen; Brain; Brain imaging; Caring; Catchment Area; Cerebrospinal Fluid; Clinical; Cognitive; Collaborations; Communities; Contracts; Data; Development; Diagnosis; Diagnostic; Disease; Early Diagnosis; Education; Education and Outreach; Evaluation; Family; Family Caregiver; Funding; Genetic; Goals; Grant; Hispanics; Informatics; Institution; Interdisciplinary Study; Investments; Latino; Leadership; Life; Magnetic Resonance Imaging; Measurement; Mentorship; Minority; Modeling; National Institute on Aging; Native Americans; Participant; Patients; Persons; Philanthropic Fund; Positron-Emission Tomography; Prevention Research; Prevention therapy; Prevention trial; Process; Productivity; Publications; Research; Research Personnel; Research Training; Resource Sharing; Resources; Risk; Role; Sampling; Secure; Strategic Planning; Testing; Training Support; Underrepresented Populations; Update; Validation; Vision; blood-based biomarker; brain tissue; clinical care; clinical research site; data management; data resource; education research; fight against; innovation; metropolitan; neuropathology; next generation; outreach; outreach program; preclinical study; prevention evaluation; programs; recruit; statistics; tau Proteins; therapy development; tool; training opportunity

OVERALL — PROJECT SUMMARY/ABSTRACT Over the last 20 years, Arizona researchers established NIA's first statewide Alzheimer's Disease Center and the nation's most extensive statewide collaboration in Alzheimer's disease (AD) research. They made pioneering contributions to the unusually early detection, tracking and study of AD and the accelerated evaluation of AD prevention therapies. The Center includes researchers from seven organizations, six in the Phoenix metropolitan area and one in Tucson. It has supported 150 researchers from organizations across the state and helping them to generate more than $2 billion in new grants, contracts, philanthropic, state and organizational investments. The Arizona AD Research Center (ADRC) will capitalize on the Center's leadership, statewide collaborative model, major organizational commitments, and extensively shared scientific resources and its very existence to make the scientific fight against AD a top priority in the state. Its resources, strategic plan, and related programs and prevention trials are specifically intended to set the stage for promising blood tests to transform AD/ADRD research, treatment development, and care, include persons from diverse backgrounds, find an effective prevention therapy by 2025, and fulfill National Alzheimer's Project Act (NAPA) goals. We will use ADRC, organizational and philanthropic funds to provide an extraordinary resource of data and blood samples for neuropathological study and diagnostic validation of BBBs for ADRD using blood samples from several hundred brain donors in the last years of life who have comprehensive neuropathological assessments after they die. The overall goals of the Center will be accomplished through coordinated activities of its six Cores and the Research Education Component (REC). The Administrative Core will provide the scientific leadership to the ADRC as a whole. The multi-site Clinical Core will perform standard evaluations and collect UDS and additional data on all participants, including a large number of Hispanic/Latino and Native American participants. The Neuropathology Core will provide neuropathologic diagnoses and process, store and distribute postmortem brain tissue, including from those who provided blood samples in the last 1-2 years of their lives. The Biomarker Core will support and provide access to genetics, brain imaging (MRI, amyloid PET, tau PET), cerebrospinal fluid (CSF) and BBBs of AD. The Outreach, Recruitment and Engagement (ORE) Core will support the efforts of the Clinical and Neuropathology Core, providing a range of educational and outreach programs for healthy adults, patients and family caregivers in our Center's catchment area, including from Arizona's large Hispanic/Latino and Native American communities. The Data Management and Statistics Core will support all the data management, informatics and statistical needs of the Cores and Center. The REC will coordinate closely with each of the Cores and leverage external partnership with two Resource Centers for Minority Aging Research (RCMARs) to attract and support the development of new researchers and clinicians. Together these activities will help set the stage for BBBs to revolutionize ADRD research, treatment and care, inform the study of preclinical AD, and help provide the best possible change to find and support the approval of an AD prevention therapy in 2025.

总体 - 项目摘要/摘要 在过去的20年中，亚利桑那州的研究人员建立了NIA的第一个全州阿尔茨海默氏病中心， 该国在阿尔茨海默氏病（AD）研究方面最广泛的全州合作。他们开创了开拓者 对AD的异常早期检测，跟踪和研究的贡献以及AD的加速评估 预防疗法。该中心包括来自七个组织的研究人员，菲尼克斯大都会的六个 区域和一个在图森。它支持了全州组织的150名研究人员，并帮助他们 产生超过20亿美元的新赠款，合同，慈善，州和组织投资。 亚利桑那州广告研究中心（ADRC）将利用该中心的领导 模型，主要组织承诺，并广泛地共享科学资源及其存在 将与AD的科学斗争置于该州的重中之重。它的资源，战略计划及相关计划 并专门针对预防试验为承诺血液测试奠定了基础，以转化AD/ADRD 研究，治疗开发和护理包括来自潜水员背景的人，找到有效的人 到2025年预防疗法，并实现阿尔茨海默氏症的国家项目法案（NAPA）目标。我们将使用ADRC， 组织和慈善资金，为数据和血液样本提供非凡资源 使用数百个血液样本对ADRD的神经病理学研究和诊断验证 大脑捐献者在生命的最后几年，他们死后进行了全面的神经病理学评估。 该中心的总体目标将通过其六个核心和研究的协调活动来实现 教育部分（REC）。行政核心将为ADRC提供科学领导 所有的。多站点临床核心将执行标准评估，并收集所有数据 参加者，包括大量西班牙裔/拉丁裔和美国原住民参与者。神经病理学 核心将提供神经病理学诊断和过程，存储和分发验尸后脑组织，包括 从那些在生命的最后1 - 2年中提供血液样本的人。生物标志物核心将支持并 提供遗传学，脑成像（MRI，淀粉样蛋白PET，TAU PET），脑脊液（CSF）和BBB 广告。外展，招聘和参与（矿石）核心将支持临床和 神经病理学核心，为健康的成人，患者和 我们中心集水区的家庭护理人员，包括亚利桑那州的大西班牙裔/拉丁裔和本地人 美国社区。数据管理和统计核心将支持所有数据管理， 核心和中心的信息和统计需求。 REC将与每个核心紧密协调 并利用与两个资源中心的外部伙伴关系，用于少数族裔老化研究（RCMARS）吸引 并支持新研究人员和临床医生的发展。这些活动共同有助于建立舞台 BBB彻底改变ADRD研究，治疗和护理，告知临床前广告的研究，并帮助 提供最好的更改，以查找和支持2025年的AD预防疗法的批准。